Brief: Day One Doses First Patients In Phase 1B/2 Study With Tovorafenib And Pimasertib In RAF-Altered Solid Tumors

Day One Biopharmaceuticals

23/05/2022 14:10

May 23 (Reuters) - Day One Biopharmaceuticals Inc  DAWN.O :
    * DAY ONE ANNOUNCES FIRST PATIENTS DOSED IN PHASE 1B/2
COMBINATION
STUDY WITH TOVORAFENIB (DAY101) AND PIMASERTIB IN RAF-ALTERED
SOLID TUMORS

Source text for Eikon:  ID:nGNX7qXWq6 
Further company coverage:  DAWN.O 

 ((Reuters.Briefs@thomsonreuters.com;))